Home KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
 

Keywords :   


KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award

2015-10-28 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. Language: English Contact: Media:Pamela Eisele, 267-305-3558 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: product usa prix award

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11ISAMI REBELS16oz
24.11 Z
24.11
24.11 4 trail lite
24.11n-buna song selection
24.11()//
24.11MTG 4
24.11 Jade Flufy Crew Sweat
More »